On October 7, 2022 BridGene Biosciences, Inc., a biotechnology company using a proprietary chemoproteomics technology to discover and develop small molecules for high value, traditionally undruggable targets, reported that two abstracts featuring the application of the company’s proprietary chemoproteomic platform IMTAC and the company’s leading program TEAD inhibitors, have been accepted for poster presentation and discussion sessions at the 34th (ENA 2022) European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI), and American Association for Cancer Research (AACR) (Free AACR Whitepaper) Symposium, which is being held October 26-28, 2022, in Barcelona (Press release, Bridgene Biosciences, OCT 7, 2022, View Source [SID1234621839]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
ENA 2022 will feature experts in cancer drug development and translational research who facilitate in-depth scientific discussions on the latest developments in targets and drugs from pre-clinical and phase I settings.
BridGene’s IMTAC enables the screening of small molecules against the whole proteome or selected targets in live cells to discover drug candidates for traditionally undruggable targets that are responsible for destructive diseases, including multiple types of cancer.
"We are delighted to announce that two abstracts have been accepted for presentation at ENA 2022. The abstracts feature research highlighting the capabilities of our IMTAC platform to identify novel therapeutic targets and novel compounds to drug ‘hard to drug’ targets," commented Ping Cao, Ph.D., Co-founder and CEO of BridGene Biosciences. "This symposium is internationally renowned for the quality of ground-breaking data presented. Our research being featured twice reflects the outstanding value of BridGene’s unique technology in drug discovery and development."